Breaking News

Financial Report: Hospira

February 13, 2013

Specialty Injectable sales up 12% in the quarter


4Q Revenues: $1.1 billion (+8%)

4Q Earnings: $5.3 million (loss of $214 million 4Q11)

FY Revenues: $4.1 billion (+1%)

FY Earnings: $44.2 million (loss of $9.4 million FY11)

Comments: Growth in the quarter was driven strong sales of Specialty Injectable Pharmaceutical (SIP) products, up 12% to $696 million, including Precedex globally and oncolytic oxaliplatin in the U.S., as well as higher volumes for certain products in the EMEA region. SIP sales in the Americas were  $539.6 million, up 13%; EMEA sales were $83.3 million, up 14%; APAC sales were flat at $73.3 million.
blog comments powered by Disqus
  • Staying Ahead in the Small Molecule Space

    Staying Ahead in the Small Molecule Space

    Dr. Matthew Moorcroft, VP Global Marketing, Cambrex||September 8, 2016
    Understand what is happening in the market and react accordingly

  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • Patent Law  and Contract Manufacturing

    Patent Law and Contract Manufacturing

    Beverly W. Lubit, Member of the Firm, Chiesa Shahinian & Giantomasi||September 8, 2016
    Analyzing the impact of The Medicines Co. vs. Hospira Inc. decision